Linked Data API

Show Search Form

Search Results

1715607
registered interest false more like this
date remove filter
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care remove filter
answering dept sort name Health and Social Care more like this
hansard heading Carbamazepine more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, whether she has had recent discussions with Novartis on the adequacy of supply of the epilepsy medication Tegretol. more like this
tabling member constituency Hornsey and Wood Green remove filter
tabling member printed
Catherine West more like this
uin 24690 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-05-09more like thismore than 2024-05-09
answer text <p>The Department has been working intensively to address issues with the supply of some epilepsy medications, and as a result we have helped to resolve issues with Tegretol 200 milligram and 400 milligram prolonged release tablets, and Tegretol 100 milligram immediate release tablets. We are aware of a shortage of Tegretol 100 milligram/5 millilitre liquid, but have been advised that resupplies are expected this month. We are continuing to work closely with manufacturers, including Novartis, to help ensure the continued supply of these medicines for patients in the United Kingdom, for example by asking suppliers to expedite deliveries.</p><p>Whilst we can’t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals, so they can advise and support their patients.</p>
answering member constituency Pendle more like this
answering member printed Andrew Stephenson more like this
question first answered
less than 2024-05-09T13:04:37.167Zmore like thismore than 2024-05-09T13:04:37.167Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4523
label Biography information for Catherine West more like this
1715632
registered interest false more like this
date remove filter
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care remove filter
answering dept sort name Health and Social Care more like this
hansard heading Phramacy: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps she is taking to help tackle shortages of medicines in pharmacies. more like this
tabling member constituency Hornsey and Wood Green remove filter
tabling member printed
Catherine West more like this
uin 24691 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-05-09more like thismore than 2024-05-09
answer text <p>The Department has a responsibility to work with United Kingdom medicine license holders, to help ensure continuity of supply. We monitor and manage medicine supply at a national level, so that stocks remain available to meet regional and local demand. There are approximately 14,000 medicines licensed for supply in the UK, and the overwhelming majority are in good supply. The medicine supply chain is complex, global, and highly regulated, and supply issues can be caused by a range of factors. For example, suppliers can encounter manufacturing problems, difficulty accessing raw materials, and surges in demand. These are commonly cited as the drivers of recent supply issues, which have affected many countries, not just the UK.</p><p>Whilst we can’t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients at a national level. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals including pharmacists, so they can advise and support their patients.</p>
answering member constituency Pendle more like this
answering member printed Andrew Stephenson more like this
question first answered
less than 2024-05-09T12:56:25.73Zmore like thismore than 2024-05-09T12:56:25.73Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4523
label Biography information for Catherine West more like this